The findings indicated that the treatment targets were primarily enriched in pathways such as the “AGE-RAGE signaling pathway in diabetic complications,” “IL-17 signaling pathway,” “p53 signaling pathway,” and “TNF signaling pathway.” These pathways exert substantial influence on the release of inflammatory factors, thereby impacting UC and T2DM. The gene discussed is TP53; the disease is type 2 diabetes mellitus.